Cell treatment in Bulgaria: EU membership does not replace product-level verification
Bulgaria has been an EU Member State since 2007, but membership and lower operating costs do not automatically authorise a product, trial, exemption or therapeutic claim.
Separate the healthcare facility from the medicinal product. A facility licence covers defined activities at an establishment. Tissue-and-cell permissions, manufacturing authorisations, clinical-trial approval and marketing authorisation address different scopes and must be checked separately.
For an ATMP, ask whether the exact product and indication have central marketing authorisation, are used in an authorised clinical trial or fall under a specific national exemption. Request the reference, holder, site and conditions. A general claim of EU compliance is not enough.
For a clinical trial, verify the sponsor, protocol, EU Clinical Trials Information System identifier, Bulgarian Drug Agency decision, ethics review, sites and recruitment status. A clinic's capacity or previous trial activity does not authorise a new product or protocol.
Assess manufacturing at the relevant product and site: authorised activities, address, inspection scope, release specifications, traceability and validity. Operating cost, investment, clinician language or medical-travel infrastructure cannot demonstrate equivalent quality or outcomes.
Use the Bulgarian Drug Agency trial-approval information, European Commission ATMP overview and EMA/HMA warning as starting points. A qualified Bulgarian regulatory professional should verify clinic-specific conclusions.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Commercial price observations are heterogeneous and most cell-therapy uses remain investigational. Verify source scope, regulatory status and the proposed care with an independent qualified physician.